Get to know us

Pernix Therapeutics is a specialty pharmaceutical company that was founded in 1996. Headquartered in The Woodlands, Texas, Pernix Therapeutics primarily focuses on the sales, marketing and development of branded, generic and OTC pharmaceutical products.

For more information about Pernix Therapeutics and other available products, please visit

Omeclamox-Pak® is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. The most frequently reported adverse events with Omeclamox-Pak were diarrhea, headache, and taste perversion. No adverse events unique to triple therapy were observed. Adverse reactions were limited to those previously reported with omeprazole, clarithromycin or amoxicillin alone.







© 2015 Pernix Therapeutics     All rights reserved     OME12-WS-00 6/2012     This information is intended only for residents of the United States.